Locoregional MYCN-amplified neuroblastoma

Pediatric Blood & Cancer, 05/04/2012Madrid AML et al.

Although the patient met the criteria for high–risk neuroblastoma, because of the discordant prognostic markers they elected to treat her according to an intermediate–risk protocol. She remains event–free more than 18 months.